Edition:
United Kingdom

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.87USD
23 Feb 2018
Change (% chg)

$0.03 (+1.63%)
Prev Close
$1.84
Open
$1.86
Day's High
$1.90
Day's Low
$1.80
Volume
143,853
Avg. Vol
538,595
52-wk High
$2.87
52-wk Low
$1.32

Chart for

About

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting... (more)

Overall

Beta: 2.14
Market Cap(Mil.): $363.61
Shares Outstanding(Mil.): 149.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

16 Feb 2018

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

22 Jan 2018

BRIEF-Idera Pharmaceuticals Provides 2018 Update And Outlook

* IDERA PHARMACEUTICALS - ANTICIPATES CURRENT CASH POSITION CAPABLE OF FUNDING OPERATIONS INTO Q2 2019 Source text for Eikon: Further company coverage:

05 Jan 2018

BRIEF-U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Idera Pharmaceuticals presents positive translational and clinical data update from ongoing IMO-2125 development program

* Idera Pharmaceuticals Inc presents positive translational and clinical data update from ongoing IMO-2125 development program at the 2017 society for immunotherapy of cancer annual meeting (SITC)

09 Nov 2017

BRIEF-Idera Pharmaceuticals reports Q3 loss per share $0.10

* Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

06 Nov 2017

BRIEF-Idera Pharma announces pricing of public offering of common stock

* Idera Pharmaceuticals announces pricing of public offering of common stock

26 Oct 2017

BRIEF-Idera Pharmaceuticals provides corporate governance update

* Idera Pharmaceuticals provides corporate governance update Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Idera Pharmaceuticals announces proposed public offering of common stock

* Idera Pharmaceuticals announces proposed public offering of common stock

24 Oct 2017

Earnings vs. Estimates